High adherence to secukinumab in patients with moderate to severe psoriasis: a long-term multicenter study in a daily practice setting

Int J Dermatol. 2023 Mar;62(3):e146-e149. doi: 10.1111/ijd.16365. Epub 2022 Jul 22.
No abstract available

Publication types

  • Multicenter Study
  • Letter

MeSH terms

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized*
  • Double-Blind Method
  • Humans
  • Psoriasis*
  • Severity of Illness Index
  • Treatment Outcome

Substances

  • secukinumab
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Monoclonal